|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.19 BRL | +23.41% |
|
+26.19% | +249.31% |
| Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
| Apr. 17 | Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A | CI |
Biomm S.A. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was BRL 104.95 million compared to BRL 107.09 million a year ago. Net loss was BRL 92.56 million compared to BRL 80.26 million a year ago.
Basic loss per share from continuing operations was BRL 1.26 compared to BRL 1.18 a year ago. Diluted loss per share from continuing operations was BRL 1.26 compared to BRL 1.18 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +249.31% | 310M | |
| -3.46% | 102B | |
| +1.41% | 96.29B | |
| +2.13% | 22.18B | |
| -15.84% | 21.2B | |
| -9.21% | 18.31B | |
| -39.98% | 17.38B | |
| -14.65% | 16.36B | |
| +4.39% | 13.97B | |
| +31.35% | 12.17B |
BIOMM S.A. 
